Figure 3.

Effect of cord blood plasma (CBP) on the histopathology of Parkinson's in the brain and gut. On day 14 following induction of Parkinson's disease pathology with intraperitoneal injections of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) the therapeutic effect of CBP treatment was observed in brain and gut tissues. MPTP lesioned rats treated with CBP noted significant reduction in TH‐cell depletion in the substantia nigra (A,B) paired with a significantly decreased inflammatory response as evidenced by decreased major histocompatibility complex (MHCII) and tumour necrosis factor alpha (TNF‐α) intensity in the brain of CBP‐treated animals (C,D). Similarly, the inflammation of the gut found to be significantly reduced through decreased MHCII (E,F) and TNF‐α (G,H) intensity present in the intestinal villi of animals treated with CBP. These findings parallel the trend of behavioural improvements in these animals that received intravascular injections of plasma. *,&: P < 0.05, **: P < 0.01 Scale bar in A is 50 µm. Scale bar in C, E, G is 100 µm